MX2021014682A - Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. - Google Patents
Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.Info
- Publication number
- MX2021014682A MX2021014682A MX2021014682A MX2021014682A MX2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A MX 2021014682 A MX2021014682 A MX 2021014682A
- Authority
- MX
- Mexico
- Prior art keywords
- eye
- protein aggregation
- pharmacological agents
- treating protein
- aggregation diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
- 108010071690 Prealbumin Proteins 0.000 abstract 2
- 102000009190 Transthyretin Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010041 presbyopia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855560P | 2019-05-31 | 2019-05-31 | |
| PCT/US2020/035592 WO2020243720A1 (en) | 2019-05-31 | 2020-06-01 | Pharmacological agents for treating protein aggregation diseases of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014682A true MX2021014682A (es) | 2022-04-06 |
Family
ID=73553335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014682A MX2021014682A (es) | 2019-05-31 | 2020-06-01 | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220241247A1 (https=) |
| EP (1) | EP3976017A4 (https=) |
| JP (1) | JP2022534420A (https=) |
| CN (1) | CN114173771A (https=) |
| BR (1) | BR112021024151A2 (https=) |
| CA (1) | CA3141998A1 (https=) |
| MX (1) | MX2021014682A (https=) |
| WO (1) | WO2020243720A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4097092A1 (en) * | 2020-01-28 | 2022-12-07 | Protego Biopharma, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| US20250019352A1 (en) * | 2021-06-29 | 2025-01-16 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating ophthalmic diseases |
| WO2023009585A2 (en) * | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113523A1 (en) * | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| WO2011116123A1 (en) * | 2010-03-19 | 2011-09-22 | Irm Llc | Tafamidis for the treatment of ophthalmic diseases |
| RU2586330C2 (ru) * | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
| US9499527B2 (en) * | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9169214B2 (en) * | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| US9790269B2 (en) * | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| RU2015138891A (ru) * | 2013-03-08 | 2017-04-11 | Аллерган, Инк. | Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами |
| PE20151747A1 (es) * | 2013-03-14 | 2015-12-18 | Univ Massachusetts | Metodo para inhibir cataratas y presbicia |
| US11872236B2 (en) * | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
-
2020
- 2020-06-01 CA CA3141998A patent/CA3141998A1/en active Pending
- 2020-06-01 CN CN202080054595.2A patent/CN114173771A/zh active Pending
- 2020-06-01 US US17/615,469 patent/US20220241247A1/en not_active Abandoned
- 2020-06-01 JP JP2021570895A patent/JP2022534420A/ja active Pending
- 2020-06-01 EP EP20813466.8A patent/EP3976017A4/en active Pending
- 2020-06-01 WO PCT/US2020/035592 patent/WO2020243720A1/en not_active Ceased
- 2020-06-01 BR BR112021024151A patent/BR112021024151A2/pt not_active Application Discontinuation
- 2020-06-01 MX MX2021014682A patent/MX2021014682A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022534420A (ja) | 2022-07-29 |
| CN114173771A (zh) | 2022-03-11 |
| US20220241247A1 (en) | 2022-08-04 |
| CA3141998A1 (en) | 2020-12-03 |
| BR112021024151A2 (pt) | 2022-02-08 |
| WO2020243720A9 (en) | 2021-02-04 |
| WO2020243720A1 (en) | 2020-12-03 |
| EP3976017A4 (en) | 2023-06-14 |
| EP3976017A1 (en) | 2022-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010502A (es) | Agentes farmacológicos para el tratamiento de enfermedades oculares. | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. | |
| AR090972A1 (es) | Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX360888B (es) | Formulaciones oculares para suministro de fármaco al segmento posterior del ojo. | |
| JP2017525769A5 (https=) | ||
| EA201992658A1 (ru) | Методы лечения рекуррентной глиобластомы (rgbm) | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| EP4647125A3 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| CL2023001596A1 (es) | Composiciones y métodos para el tratamiento de enfermedades oculares | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| MX2024003580A (es) | Metodos de tratamiento de enfermedades inflamatorias oculares. | |
| HRP20190561T1 (hr) | Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom | |
| EP4729124A2 (en) | Modulation of wnt5a to treat glaucoma | |
| EA202193178A1 (ru) | Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина | |
| MX2021011727A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| MX2021015796A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| MX2021012857A (es) | Composiciones y metodos utilizables para el tratamiento del ojo seco. | |
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| EA201990559A1 (ru) | Комбинированная терапия |